Streetbeat News

Regulatory

GLD

IWM

SPY

TLT

UUP

August inflation in the U.S. fell to 2.5%, but core inflation remains high at 3.2%, affecting market expectations for a Fed rate cut. The SPDR S&P 500 ETF Trust (SPY) fell 0.2%, iShares Russell 2000 ETF (IWM) dropped 1%, and the Invesco DB USD Index Bullish Fund ETF (UUP) rose 0.1%.

Portfolio Pulse from Piero Cingari

September 11, 2024 | 2:12 pm

UPS

The U.S. Postal Service announced it will stop offering discounted rates through Negotiated Service Agreements for packages entered by consolidators. This decision could impact shipping costs and logistics for companies relying on these discounts.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 2:04 pm

APDN

Applied DNA Sciences (APDN) stock surged 37% after expanding its mpox testing services, approved by regulatory bodies. The company aims to enhance testing access in New York and other states.

Portfolio Pulse from Henry Khederian

September 11, 2024 | 2:01 pm

ALLR

Allarity Therapeutics shares declined following a 1-for-30 reverse stock split aimed at regaining Nasdaq listing compliance.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:57 pm

CCJ

DNN

LEU

UEC

UUUU

VGK

Russian President Vladimir Putin has suggested considering export restrictions on certain goods, including uranium, titanium, and nickel. This could impact global markets and companies involved in these commodities.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:51 pm

REGN

SNY

Sanofi and Regeneron's Dupixent shows positive results in treating chronic spontaneous urticaria and bullous pemphigoid, with significant improvements over placebo. The drug's efficacy in these conditions could lead to further FDA approval.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 1:35 pm

JNJ

Johnson & Johnson's Phase 2 SKIPPirr study shows a significant reduction in infusion-related reactions for Rybrevant in lung cancer patients. The Phase 3 MARIPOSA study also highlights improved survival rates with Rybrevant plus Lazcluze compared to osimertinib. The FDA approved Rybrevant plus Lazcluze as a first-line therapy for EGFR-mutated NSCLC.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 1:08 pm

APDN

Applied DNA Sciences, Inc. has expanded its clinical testing services to include detection of Mpox Clade I and Clade II, following interactions with regulatory bodies.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:05 pm

APIE

BABA

JHEM

PDD

Jack Ma encourages Alibaba to embrace competition as a growth driver. Alibaba faces challenges, including a domestic price war and missed earnings estimates. The company recently joined China's Stock Connect, potentially unlocking $12 billion in funds.

Portfolio Pulse from Anusuya Lahiri

September 11, 2024 | 12:59 pm

HYTNF

HYTN Innovations Inc. (OTCPK:HYTNF) has partnered with 4C LABS to supply medical marijuana to the UK, with plans to expand into Germany and Australia. This collaboration will leverage HYTN's GMP-certified manufacturing to produce and distribute cannabis products internationally.

Portfolio Pulse from Nina Zdinjak

September 11, 2024 | 12:56 pm